Surgical Pathology of the Ovaries, Second Edition

Russell, Peter; Farnsworth, Annabelle; Mooney, Eoghan E.

doi:10.1097/00004347-199807000-00017

Cited by 12 publications

(21 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10 Morphologically, the presence of a well developed corpus luteum of pregnancy adjacent to the tumour may be indicative of a gestational origin. 7 This was not seen in our case.…”

Section: Discussioncontrasting

confidence: 57%

“…6 Pure nongestational ovarian choriocarcinomas are extremely rare and highly malignant tumours which frequently metastasize through the lymphatics with intra-abdominal spread. 7,8 Also, the treatment regimen for the two differs.…”

Section: Discussionmentioning

confidence: 99%

“…2,3 Pure non-gestational choriocarcinoma of the ovary is an extremely rare neoplasm, with only a few reported cases in literature. 4,5 In general, majority of the non-gestational type have been clinically diagnosed in patients who were sexually immature, unable to conceive or had never had sexual intercourse.…”

Section: Introductionmentioning

confidence: 99%

“…Pure choriocarcinoma has been defined as a tumour that does not include other germ cell tumour elements. 2 It is important to differentiate between cases of nongestational or gestational choriocarcinoma of the ovary, as non-gestational choriocarcinoma has a poorer prognosis compared to gestational. Also, the treatment regimen for the two differs.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Primary pure non-gestational choriocarcinoma of ovary: a rare case report

Rawal

Ahluwalia

Yadav

et al. 2017

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

Germ cell malignancies represent 15% of ovarian cancers. Choriocarcinoma is a malignant tumour with trophoblastic differentiation. It may be gestational or non-gestational and may be a primary tumour or metastatic from other organs. Pure non-gestational choriocarcinoma is an extremely rare neoplasm, with reports of only a few cases. This study reports a rare case of non-gestational pure choriocarcinoma in a postmenarcheal young female and describes details of the tumour, including the clinicopathological findings. A young female presented with sudden onset anxiety, abdominal distention, severe abdominal pain, and severe pallor. Clinically, she was diagnosed as a case of ruptured ectopic pregnancy, and was taken up for emergency laparotomy. A right ovarian mass of 5X7 cm was seen, which was ruptured and was bleeding profusely. Right salpingo-oophorectomy was done, and it was diagnosed histopathologically as primary pure non-gestational choriocarcinoma of ovary. This case report describes the histopathological and immunohistochemical findings of this rare entity, as well as the various methods to differentiate between cases of non-gestational and gestational choriocarcinoma of the ovary. This is important as non-gestational choriocarcinoma has a poorer prognosis in comparison with gestational. Also, the treatment regimen for the two differs.

show abstract

“…10 Morphologically, the presence of a well developed corpus luteum of pregnancy adjacent to the tumour may be indicative of a gestational origin. 7 This was not seen in our case.…”

Section: Discussioncontrasting

confidence: 57%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Primary pure non-gestational choriocarcinoma of ovary: a rare case report

Rawal

Ahluwalia

Yadav

et al. 2017

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

show abstract

“…In the postmenopausal ovary, hypertrophied stromal cells are localized mainly at the periphery and hilus (Russell & Bannatyne 1989). These stromal cells contain both 3 -HSD and type 5 17 -HSD, thus permitting the transformation of DHEA into 4-dione and then into testosterone.…”

Section: Steroidogenic Enzymesmentioning

confidence: 99%

Is dehydroepiandrosterone a hormone?

Labrie¹,

Luu‐The²,

Bélanger³

et al. 2005

Journal of Endocrinology

384

242

View full text Add to dashboard Cite

Dehydroepiandrosterone (DHEA) is not a hormone but it is a very important prohormone secreted in large amounts by the adrenals in humans and other primates, but not in lower species. It is secreted in larger quantities than cortisol and is present in the blood at concentrations only second to cholesterol. All the enzymes required to transform DHEA into androgens and/or estrogens are expressed in a cellspecific manner in a large series of peripheral target tissues, thus permitting all androgen-sensitive and estrogensensitive tissues to make locally and control the intracellular levels of sex steroids according to local needs. This new field of endocrinology has been called intracrinology. In women, after menopause, all estrogens and almost all androgens are made locally in peripheral tissues from DHEA which indirectly exerts effects, among others, on bone formation, adiposity, muscle, insulin and glucose metabolism, skin, libido and well-being. In men, where the secretion of androgens by the testicles continues for life, the contribution of DHEA to androgens has been best evaluated in the prostate where about 50% of androgens are made locally from DHEA. Such knowledge has led to the development of combined androgen blockade (CAB), a treatment which adds a pure anti-androgen to medical (GnRH agonist) or surgical castration in order to block the access of the androgens made locally to the androgen receptor. In fact, CAB has been the first treatment demonstrated to prolong life in advanced prostate cancer while recent data indicate that it can permit long-term control and probably cure in at least 90% of cases of localized prostate cancer. The new field of intracrinology or local formation of sex steroids from DHEA in target tissues has permitted major advances in the treatment of the two most frequent cancers, namely breast and prostate cancer, while its potential use as a physiological HRT could well provide a physiological balance of androgens and estrogens, thus offering exciting possibilities for women's health at menopause.

show abstract